7 completed, 4 active not recruiting, 3 recruiting, 1 not yet recruiting. 11 Phase 2, 6 Phase 1, 4 Phase 3.
Follow bomedemstat: new trials by email Literature Review of bomedemstat trials Research Report on bomedemstat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis bomedemstat - Myelofibrosis | Phase 2 | Not yet recruiting | United Lincolnshire Hospitals NHS Trust | 40 | 2026-11-01 | 2026-02-20 |
| A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025). Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b - Polycythemia Vera | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 380 | 2026-10-21 | 2026-10-21 |
| A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023) Bomedemstat - Hepatic Insufficiency | Phase 1 | Completed | Merck Sharp & Dohme LLC | 9 | 2025-08-20 | 2026-02-25 |
| Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020) bomedemstat, carbamazepine - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2024-10-02 | 2025-03-18 |
| Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) Bomedemstat, Hydroxyurea, Bomedemstat placebo - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 300 | 2024-07-16 | 2026-08-27 |
| A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 400 | 2024-05-23 | 2026-04-02 |
| A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) Bomedemstat, Anagrelide, Busulfan - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 340 | 2023-12-31 | 2026-10-02 |
| A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004) Bomedemstat - Polycythemia Vera | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 20 | 2023-09-07 | 2026-05-07 |
| Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis Bomedemstat - Myelofibrosis | Phase 2 | Unknown | The University of Hong Kong | 40 | 2022-12-01 | 2023-05-23 |
| Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia Bomedemstat, Venetoclax - Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | Terrence J Bradley, MD | 18 | 2022-11-19 | 2026-01-08 |
| Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer Bomedemstat, Atezolizumab - Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | University of Washington | 3 | 2022-04-11 | 2024-09-26 |
| An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 81 | 2021-12-15 | 2025-09-22 |
| IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) IMG-7289 - Essential Thrombocythemia, Polycythemia Vera | Phase 2 | Active not recruiting | Terrence J Bradley, MD | 4 | 2020-10-02 | 2026-01-07 |
| Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) Bomedemstat - Essential Thrombocythemia | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 73 | 2020-09-08 | 2026-05-04 |
| Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 IMG-7289 - Thrombocythemia, Essential | Phase 2 | Active not recruiting | The University of Texas Health Science Center at San Antonio | 9 | 2020-04-09 | 2026-10-22 |
| Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) Bomedemstat - Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 1 / Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 90 | 2017-07-18 | 2024-01-10 |
| A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) bomedemstat, tretinoin - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 45 | 2016-10-06 | 2023-07-11 |
Thrombocythemia, Essential (7) · Primary Myelofibrosis (5) · Polycythemia Vera (4) · Leukemia, Myeloid, Acute (2) · Hepatic Insufficiency (1) · Myelodysplastic Syndromes (1)
Merck Sharp & Dohme LLC (6) · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (5) · Terrence J Bradley, MD (2) · The University of Hong Kong (1) · The University of Texas Health Science Center at San Antonio (1) · United Lincolnshire Hospitals NHS Trust (1) · University of Washington (1)
United States (14) · Australia (8) · United Kingdom (7) · Hong Kong (6) · Italy (6) · Germany (5) · New Zealand (4) · Israel (3) · Argentina (2) · Canada (2) · China (2) · Colombia (2) · France (2) · Hungary (2) · Japan (2)
Terrence J Bradley, MD (2) · Harinder Gill, MD (1) · Rafael Santana-Davila (1) · Zohra Nooruddin, MD (1)
2023 (3), 2018 (1), 2019 (1), P50CA228944 (1)